Nxera Pharma Co., Ltd.

4565

JP3431300007

Pharmaceuticals

Delayed Japan Exchange Other stock markets 10:30:00 2024-04-24 pm EDT			5-day change	1st Jan Change
1,521 ^JPY	+0.86%		+0.66%	+7.04%

Apr. 18	Nxera Pharma Initiates Restricted Stock Unit Plans, Starting with Shares Worth 164 Million Yen in Total in May	MT
Apr. 17	Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	MT

Sosei : 2025年満期ユーロ円建転換社債型新株予約権付社債のクリーンアップ条項による繰上償還に関するお知らせ

August 18, 2021 at 08:04 pm EDT

2025年満期ユーロ円建転換社債型新株予約権付社債のクリーンアップ条項による繰上償還に関するお知らせ

Attachments

Original document
Permalink

Disclaimer

Sosei Group Corporation published this content on 19 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 August 2021 00:03:03 UTC.

Latest news about Nxera Pharma Co., Ltd.

Nxera Pharma Initiates Restricted Stock Unit Plans, Starting with Shares Worth 164 Million Yen in Total in May	Apr. 17	MT
Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	Apr. 16	MT
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568	Apr. 16	CI
Nxera Pharma Partners with Handok c. to Distribute PIVLAZ in South Korea,	Apr. 15	MT
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for Pivlaz in South Korea	Apr. 14	CI
Nxera Pharma Appoints Patrick Branch as Head of Business Development for Japan and APAC	Apr. 03	CI
Sosei Group Corporation will Change its Name to Nxera Pharma Co., Ltd	Apr. 01	CI
Sosei Shareholders Greenlight Name Change, Top Management Appointments	Mar. 28	MT
Transcript : Sosei Group Corporation - Shareholder/Analyst Call	Mar. 26
Sosei Heptares Begins Phase 1 Trial for Novel Inflammatory Bowel Disease Treatment	Mar. 21	MT
Sosei Group Corporation Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease	Mar. 20	CI
Sosei Group Corporation Doses First Subject in a Phase 1 Trial Evaluating its Novel EP4 Receptor Agonist, HTL0033744 (HTL'744) for the Treatment of Inflammatory Bowel Disease	Mar. 20	CI
Jefferies Adjusts Sosei Group’s Price Target to 2,100 Yen From 1,800 Yen, Keeps at Buy	Mar. 12	MT
Sosei Group, Boehringer Ingelheim Enter Into License Deal for Schizophrenia Symptoms	Mar. 12	MT
Boehringer Ingelheim and Sosei Heptares Join Forces to Develop First-In-Class Treatments Targeting All Symptoms of Schizophrenia	Mar. 11	CI
Boehringer Ingelheim and Sosei Group Corporation Enter Exclusive Option-To- License Agreement	Mar. 11	CI
Japanese Shares Close Lower But Hit Fresh 52-Week High on US Rate Cut Assurance	Mar. 07	MT
Sosei Group to Get $2.5 Million Milestone Payment from Formosa Pharmaceuticals	Mar. 07	MT
Sosei Group Corporation to Receive $2.5 Million Payment from Formosa Pharmaceuticals	Mar. 06	CI
Drugmakers deepen efforts to tap into booming market for obesity drugs	Feb. 27	RE
Sosei Group Changes Names of Company, Subsidiaries	Feb. 16	MT
Transcript : Sosei Group Corporation, 2023 Earnings Call, Feb 13, 2024	Feb. 13
Jefferies Adjusts Sosei Group's Price Target to 1,800 Yen From 1,700 Yen, Keeps at Buy	Jan. 25	MT
Transcript : Sosei Group Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 01:30 PM	Jan. 10
Sosei Group Corporation Appoints Toshihiro Maeda as Chief Operating Officer	Jan. 05	CI

Chart Nxera Pharma Co., Ltd.

Duration

Period

More charts

Company Profile

Nxera Pharma Co Ltd, formerly known as Sosei Group Corp, is a Japan-based company engaged in the biopharmaceutical business that handles from drug research (drug discovery) to development and sale. The Company is mainly engaged in the pharmaceutical business. The Company is engaged in drug discovery, translational medicine, preclinical and early clinical development, as well as the research and development, import/export, packaging, and sale of pharmaceuticals. The Company also conducts structural analysis of G protein-coupled receptors (GPCRs), creates initial lead compounds, and searches for candidate products using StaR technology.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Nxera Pharma Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1,508 JPY

Average target price

2,100 JPY

Spread / Average Target

+39.26%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
NXERA PHARMA CO., LTD.	+7.04%	855M
CSL LIMITED	-2.86%	87.37B
SAMSUNG BIOLOGICS CO.,LTD.	+3.95%	41.01B
BIOGEN INC.	-21.94%	28.08B
UCB	+53.11%	24.72B
BIOMARIN PHARMACEUTICAL INC.	-5.41%	17.47B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.23%	11.69B
INCYTE CORPORATION	-17.60%	11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.96%	11.56B
SWEDISH ORPHAN BIOVITRUM AB	-0.22%	8.44B

Biopharmaceuticals

Nxera Pharma Co., Ltd.

Equities

4565

JP3431300007

Pharmaceuticals

Sosei : 2025年満期ユーロ円建転換社債型新株予約権付社債の クリーンアップ条項による繰上償還に関するお知らせ

EPS Revisions

Sosei : 2025年満期ユーロ円建転換社債型新株予約権付社債のクリーンアップ条項による繰上償還に関するお知らせ